Topic: Excessive pricing

First class action filed over Shkreli’s price-hike of Daraprim

Blue Cross and Blue Shield of Minnesota has sued former pharmaceutical company executive Martin Shkreli over his alleged scheme to monopolise the market for antiparasitic drug Daraprim.

05 March 2021

Get unlimited access to all Global Competition Review content